Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

[Peripheral facial palsy caused by severe hypertension in a three-year-old boy].

Kofoed IR, Christensen HM.

Ugeskr Laeger. 2017 Apr 24;179(17). pii: V12160911. Danish.

PMID:
28473027
2.

Involvement of patients' perspectives on treatment with noninvasive ventilation in patients with chronic obstructive pulmonary disease-A qualitative study.

Christensen HM, Huniche L, Titlestad IL.

J Clin Nurs. 2017 Apr 12. doi: 10.1111/jocn.13847. [Epub ahead of print]

PMID:
28401600
3.

Smart darting diffusion Monte Carlo: Applications to lithium ion-Stockmayer clusters.

Christensen HM, Jake LC, Curotto E.

J Chem Phys. 2016 May 7;144(17):174115. doi: 10.1063/1.4948562.

PMID:
27155633
4.

Best strategies for reducing the suicide rate in Australia: response to Pirkis.

Batterham PJ, Torok M, Krysinska K, Shand F, Calear AL, Cockayne N, Christensen HM.

Aust N Z J Psychiatry. 2016 Apr;50(4):386. doi: 10.1177/0004867416638518. No abstract available.

PMID:
27005427
5.

The Beyond Ageing Project Phase 2--a double-blind, selective prevention, randomised, placebo-controlled trial of omega-3 fatty acids and sertraline in an older age cohort at risk for depression: study protocol for a randomized controlled trial.

Cockayne NL, Duffy SL, Bonomally R, English A, Amminger PG, Mackinnon A, Christensen HM, Naismith SL, Hickie IB.

Trials. 2015 Jun 3;16:247. doi: 10.1186/s13063-015-0762-6.

6.

Common side reactions of the glycosyl donor in chemical glycosylation.

Christensen HM, Oscarson S, Jensen HH.

Carbohydr Res. 2015 May 18;408:51-95. doi: 10.1016/j.carres.2015.02.007. Epub 2015 Feb 25. Review.

PMID:
25862946
7.

The Sleep Or Mood Novel Adjunctive therapy (SOMNA) trial: a study protocol for a randomised controlled trial evaluating an internet-delivered cognitive behavioural therapy program for insomnia on outcomes of standard treatment for depression in men.

Cockayne NL, Christensen HM, Griffiths KM, Naismith SL, Hickie IB, Thorndike FP, Ritterband LM, Glozier NS.

BMC Psychiatry. 2015 Feb 5;15:16. doi: 10.1186/s12888-015-0397-x.

8.

Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.

Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Flyvbjerg A, Faber J.

Metabolism. 2014 Jan;63(1):141-9. doi: 10.1016/j.metabol.2013.09.017. Epub 2013 Oct 17.

PMID:
24140097
9.

Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction.

Christensen HM, Schou M, Goetze JP, Faber J, Frystyk J, Flyvbjerg A, Kistorp C.

BMC Cardiovasc Disord. 2013 Oct 1;13:80. doi: 10.1186/1471-2261-13-80.

10.

The need for specialist services for serious and recurrent mood disorders.

Berk M, Scott J, Macmillan I, Callaly T, Christensen HM.

Aust N Z J Psychiatry. 2013 Sep;47(9):815-8. doi: 10.1177/0004867413479407. No abstract available.

PMID:
23985792
11.

Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status.

Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Schwarz P, Faber J.

Endocrine. 2013 Jun;43(3):626-34. doi: 10.1007/s12020-012-9836-3. Epub 2012 Nov 22.

PMID:
23179776
12.

Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.

Appel JM, Zerahn B, Møller S, Christensen HM, Søgaard P, Ejlertsen B, Fogh-Andersen N, Jensen BV, Nielsen DL.

Acta Oncol. 2012 Nov;51(8):1054-61. doi: 10.3109/0284186X.2012.702920. Epub 2012 Aug 22.

PMID:
22909389
13.

α-Defensins and outcome in patients with chronic heart failure.

Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P, Raymond I, Klausen TW, Kistorp C.

Eur J Heart Fail. 2012 Apr;14(4):387-94. doi: 10.1093/eurjhf/hfs021. Epub 2012 Feb 22.

14.

Australian mental health consumers' priorities for research: qualitative findings from the SCOPE for Research project.

Banfield MA, Barney LJ, Griffiths KM, Christensen HM.

Health Expect. 2014 Jun;17(3):365-75. doi: 10.1111/j.1369-7625.2011.00763.x. Epub 2012 Jan 4.

15.

SCOPE for Research: mental health consumers' priorities for research compared with recent research in Australia.

Banfield MA, Griffiths KM, Christensen HM, Barney LJ.

Aust N Z J Psychiatry. 2011 Dec;45(12):1078-85. doi: 10.3109/00048674.2011.624084. Epub 2011 Oct 29.

PMID:
22034831
16.

SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Tooker BC, Bowler RP, Orcutt JM, Maier LA, Christensen HM, Newman LS.

Occup Environ Med. 2011 Oct;68(10):759-64. doi: 10.1136/oem.2010.058966. Epub 2011 Jan 27.

17.

A highly toxic cellular prion protein induces a novel, nonapoptotic form of neuronal death.

Christensen HM, Dikranian K, Li A, Baysac KC, Walls KC, Olney JW, Roth KA, Harris DA.

Am J Pathol. 2010 Jun;176(6):2695-706. doi: 10.2353/ajpath.2010.091007. Epub 2010 May 14.

18.

A deleted prion protein that is neurotoxic in vivo is localized normally in cultured cells.

Christensen HM, Harris DA.

J Neurochem. 2009 Jan;108(1):44-56. doi: 10.1111/j.1471-4159.2008.05719.x. Epub 2008 Nov 12.

19.

Prion protein lacks robust cytoprotective activity in cultured cells.

Christensen HM, Harris DA.

Mol Neurodegener. 2008 Aug 21;3:11. doi: 10.1186/1750-1326-3-11.

20.

Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies.

Biasini E, Seegulam ME, Patti BN, Solforosi L, Medrano AZ, Christensen HM, Senatore A, Chiesa R, Williamson RA, Harris DA.

J Neurochem. 2008 Jun 1;105(6):2190-204. doi: 10.1111/j.1471-4159.2008.05306.x.

Supplemental Content

Loading ...
Support Center